Tesamorelin
What is Tesamorelin?
Tesamorelin is a potent synthetic GHRH analogue, most famous for its FDA approval to treat HIV-associated lipodystrophy (excess abdominal fat). It is considered the strongest GHRH peptide for visceral fat reduction.
Mechanism of Action
It binds to GHRH receptors with high affinity and stability due to its N-terminal modification (trans-3-hexenoic acid). It potently stimulates pulsatile GH release, leading to significant reductions in visceral adipose tissue (VAT).
Benefits
- Significant reduction in visceral belly fat
- Increases IGF-1 levels
- Improves lipid profile (cholesterol/triglycerides)
- Enhances cognition in some studies
- Muscle toning
Typical Dosage
- 1mg daily (standard)
- 2mg daily (clinical dose)
Side Effects
- Injection site reactions
- Arthralgia (joint pain)
- Potential insulin resistance (monitor blood glucose)
- Fluid retention
Dosage Protocol
Administer 1–2 mg subcutaneously once daily, typically in the morning or before bed. The clinical dose for visceral fat reduction is 2 mg daily. It is best taken on an empty stomach to maximize GH release. Cycles are often 3–6 months to see significant visceral fat reduction. Reconstitute carefully as it can be fragile.
Reconstitution
Dosing Schedule
Standard Protocol
- •Daily: 1 mg subcutaneous
- •Timing: Before bed or morning (fasted)
Advanced / Titration
- •Daily: 2 mg subcutaneous
- •Cycle: 3-6 months for max fat loss
Negative Interactions
- Active malignancy
- Pregnancy
- Hypersensitivity